Metachromatic Leukodystrophy (MLD): Clinical Trials

5 trials for Metachromatic Leukodystrophy (MLD), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Terminated 1
Phase 13Completed 2, Terminated 1

Follow Metachromatic Leukodystrophy (MLD): new trials by email Literature Review of Metachromatic Leukodystrophy (MLD) trials Research Report on Metachromatic Leukodystrophy (MLD)

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
SHP611 - Metachromatic Leukodystrophy (MLD)
Phase 2CompletedShire362019-05-132026-07-10
An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy
HGT-1110 - Metachromatic Leukodystrophy (MLD)
Phase 1 / Phase 2CompletedShire242013-05-232026-04-21
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)
Recombinant human arylsulfatase A - Metachromatic Leukodystrophy (MLD)
Phase 1 / Phase 2CompletedShire242012-02-022021-06-14
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
hematopoietic stem cell infusion - Hurler Syndrome (MPS I), Hurler-Scheie Syndrome
Phase 1 / Phase 2TerminatedTalaris Therapeutics Inc.32011-04-012023-04-12
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Campath-1H, Cyclophosphamide, Busulfan - Mucopolysaccharidosis, Hurler Syndrome
Phase 2CompletedMasonic Cancer Center, University of Minnesota462009-12-012018-02-05

Narrower conditions

Leukodystrophy, Metachromatic (5)  ·  Adrenoleukodystrophy (2)  ·  Leukodystrophy, Globoid Cell (2)  ·  Mucopolysaccharidosis I (2)  ·  Mucopolysaccharidosis II (2)  ·  alpha-Mannosidosis (2)  ·  Aspartylglucosaminuria (1)  ·  Fucosidosis (1)  ·  Mucopolysaccharidoses (1)  ·  Mucopolysaccharidosis III (1)  ·  Mucopolysaccharidosis VI (1)  ·  Mucopolysaccharidosis VII (1)  ·  Niemann-Pick Diseases (1)  ·  Peroxisomal Disorders (1)  ·  Sandhoff Disease (1)

Broader conditions

Brain Diseases (5)  ·  Brain Diseases, Metabolic (5)  ·  Brain Diseases, Metabolic, Inborn (5)  ·  Central Nervous System Diseases (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Demyelinating Diseases (5)  ·  Genetic Diseases, Inborn (5)  ·  Hereditary Central Nervous System Demyelinating Diseases (5)  ·  Leukoencephalopathies (5)  ·  Lipid Metabolism Disorders (5)  ·  Lipid Metabolism, Inborn Errors (5)  ·  Lipidoses (5)  ·  Lysosomal Storage Diseases (5)  ·  Lysosomal Storage Diseases, Nervous System (5)  ·  Metabolic Diseases (5)

Interventions

Stem Cell Transplantation (2)  ·  Alemtuzumab (1)  ·  Busulfan (1)  ·  Cyclophosphamide (1)  ·  Cyclosporine (1)  ·  Mycophenolic Acid (1)

Sponsors

Shire (3)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Talaris Therapeutics Inc. (1)

Countries

France (3)  ·  Germany (3)  ·  Japan (3)  ·  United States (3)  ·  Australia (2)  ·  Brazil (2)  ·  Denmark (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Canada (1)  ·  Czechia (1)  ·  Greece (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)

Top investigators

Paul Orchard, MD (1)  ·  Suzanne T Ildstad, MD (1)

Results publications

PMID 32792226

NIH funding

2018 (1)